4/29/2026
Chiesi Drops $1.9 Billion to Snag KalVista — and the First Oral HAE Treatment on the Market
Italian biopharmaceutical group Chiesi has agreed to acquire Nasdaq-listed KalVista Pharmaceuticals (KALV) for $27.00 per share in an all-cash deal valued at approximately $1.9 billion — the company’s largest acquisition in its 90-year history and a major bet on the rare disease space.
0
3 min read
